Contact Information

Call us at: (614) 355-2787

Email Nizar Y. Saad, PhD

Center for Gene Therapy700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Nizar Y. Saad

Research

Lab(s)

Center for Gene Therapy

Dr. Saad’s research interests are in understanding the pathobiology of inherited neuromuscular disorders, and in the discovery of circulating exosome-based biomarkers and the development of viral (Adeno-Associated Virus) and non-viral (Exosomes) based gene therapies towards these disorders and other rare genetic diseases (Laminopathies). Publications

                  Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nat Commun. 2021 Dec 8; 12: 7128.

                


                  Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight. 2018 Nov 15; 3: 

                


                  Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev. 2018 Mar 16; 8: 121-130.

View More Publications

Biography

Nizar Y. Saad, PhD, is a research assistant professor at The Ohio State University College of Medicine, and a principal investigator at the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Saad is an experienced RNA biologist and gene therapy specialist. Dr. Saad also serves on the New Investigator Committee, the Musculo-Skeletal Gene & Cell Therapy Committee and the Oligonucleotide and RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy (ASGCT). Dr. Saad earned his doctorate degree in life sciences (biochemistry and molecular biology) from the University of Strasbourg. Dr. Saad then completed two consecutive postdoctoral training, in the lab of Tina Henkin, PhD, at The Ohio State University, where he investigated bacterial T-box riboswitch-based regulation of gene expression, and in the lab of Scott Harper, PhD, at Nationwide Children’s Hospital, where he developed gene and drug-based therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) by inducing the expression of a natural DUX4-targerting miRNA.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Awards, Honors & Organizations

Elsevier WMS Membership Award, World Muscle Society, 2018 Certificate of Recognition from the President of The Ohio State University, The Ohio State University, 2014 FEBS Summer Fellowship, University of Strasbourg, 2009 Member, International Society for Extracellular Vesicles, 2021 - Present Member, American Society for Gene and Cell Therapy, USA, 2019 - Present Member, World Muscle Society, 2018 - Present Member, National Postdoctoral Association, USA, 2013 - 2019

Education

Graduate School

University of Strasbourg

Date Completed: 08/10/2011

Professional Experience

2019 - 2021 Nationwide Children’s Hospital, Research Scientist2015 - 2019 Nationwide Children’s Hospital, Postdoctoral Fellow2013 - 2015 The Ohio State University, Postdoctoral Fellow

Contact Information

Center for Gene Therapy

Call us at: (614) 355-2787

Email Nizar Y Saad 2

                    700 Children's DriveColumbus, OH 43205 (map)

Connect with Nizar Y. Saad

Connect on LinkedIn

Connect on ResearchGate

Contact Information

Call us at: (614) 355-2787

Email Nizar Y. Saad, PhD

Center for Gene Therapy700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Nizar Y. Saad

Research

Lab(s)

Center for Gene Therapy

Dr. Saad’s research interests are in understanding the pathobiology of inherited neuromuscular disorders, and in the discovery of circulating exosome-based biomarkers and the development of viral (Adeno-Associated Virus) and non-viral (Exosomes) based gene therapies towards these disorders and other rare genetic diseases (Laminopathies). Publications

                  Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nat Commun. 2021 Dec 8; 12: 7128.

                


                  Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight. 2018 Nov 15; 3: 

                


                  Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev. 2018 Mar 16; 8: 121-130.

View More Publications

Biography

Nizar Y. Saad, PhD, is a research assistant professor at The Ohio State University College of Medicine, and a principal investigator at the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Saad is an experienced RNA biologist and gene therapy specialist. Dr. Saad also serves on the New Investigator Committee, the Musculo-Skeletal Gene & Cell Therapy Committee and the Oligonucleotide and RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy (ASGCT). Dr. Saad earned his doctorate degree in life sciences (biochemistry and molecular biology) from the University of Strasbourg. Dr. Saad then completed two consecutive postdoctoral training, in the lab of Tina Henkin, PhD, at The Ohio State University, where he investigated bacterial T-box riboswitch-based regulation of gene expression, and in the lab of Scott Harper, PhD, at Nationwide Children’s Hospital, where he developed gene and drug-based therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) by inducing the expression of a natural DUX4-targerting miRNA.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Awards, Honors & Organizations

Elsevier WMS Membership Award, World Muscle Society, 2018 Certificate of Recognition from the President of The Ohio State University, The Ohio State University, 2014 FEBS Summer Fellowship, University of Strasbourg, 2009 Member, International Society for Extracellular Vesicles, 2021 - Present Member, American Society for Gene and Cell Therapy, USA, 2019 - Present Member, World Muscle Society, 2018 - Present Member, National Postdoctoral Association, USA, 2013 - 2019

Education

Graduate School

University of Strasbourg

Date Completed: 08/10/2011

Professional Experience

2019 - 2021 Nationwide Children’s Hospital, Research Scientist2015 - 2019 Nationwide Children’s Hospital, Postdoctoral Fellow2013 - 2015 The Ohio State University, Postdoctoral Fellow

Contact Information

Center for Gene Therapy

Call us at: (614) 355-2787

Email Nizar Y Saad 2

                    700 Children's DriveColumbus, OH 43205 (map)

Connect with Nizar Y. Saad

Connect on LinkedIn

Connect on ResearchGate

Contact Information

Call us at: (614) 355-2787

Email Nizar Y. Saad, PhD

Center for Gene Therapy700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Nizar Y. Saad

Contact Information

  • Call us at:
  • (614) 355-2787
  • Email Nizar Y. Saad, PhD
  • Center for Gene Therapy700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Nizar Y. Saad

Research

Lab(s)

Center for Gene Therapy

Dr. Saad’s research interests are in understanding the pathobiology of inherited neuromuscular disorders, and in the discovery of circulating exosome-based biomarkers and the development of viral (Adeno-Associated Virus) and non-viral (Exosomes) based gene therapies towards these disorders and other rare genetic diseases (Laminopathies). Publications

                  Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nat Commun. 2021 Dec 8; 12: 7128.

                


                  Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight. 2018 Nov 15; 3: 

                


                  Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev. 2018 Mar 16; 8: 121-130.

View More Publications

Research

Lab(s)

Center for Gene Therapy

Dr. Saad’s research interests are in understanding the pathobiology of inherited neuromuscular disorders, and in the discovery of circulating exosome-based biomarkers and the development of viral (Adeno-Associated Virus) and non-viral (Exosomes) based gene therapies towards these disorders and other rare genetic diseases (Laminopathies). Publications

                  Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nat Commun. 2021 Dec 8; 12: 7128.

                


                  Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight. 2018 Nov 15; 3: 

                


                  Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev. 2018 Mar 16; 8: 121-130.

View More Publications

Research

Lab(s)

Center for Gene Therapy

Dr. Saad’s research interests are in understanding the pathobiology of inherited neuromuscular disorders, and in the discovery of circulating exosome-based biomarkers and the development of viral (Adeno-Associated Virus) and non-viral (Exosomes) based gene therapies towards these disorders and other rare genetic diseases (Laminopathies). Publications

                  Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nat Commun. 2021 Dec 8; 12: 7128.

                


                  Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight. 2018 Nov 15; 3: 

                


                  Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev. 2018 Mar 16; 8: 121-130.

View More Publications

Lab(s)

Center for Gene Therapy

Dr. Saad’s research interests are in understanding the pathobiology of inherited neuromuscular disorders, and in the discovery of circulating exosome-based biomarkers and the development of viral (Adeno-Associated Virus) and non-viral (Exosomes) based gene therapies towards these disorders and other rare genetic diseases (Laminopathies). Publications

                  Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nat Commun. 2021 Dec 8; 12: 7128.

                


                  Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight. 2018 Nov 15; 3: 

                


                  Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev. 2018 Mar 16; 8: 121-130.

View More Publications

Lab(s)

Center for Gene Therapy

Dr. Saad’s research interests are in understanding the pathobiology of inherited neuromuscular disorders, and in the discovery of circulating exosome-based biomarkers and the development of viral (Adeno-Associated Virus) and non-viral (Exosomes) based gene therapies towards these disorders and other rare genetic diseases (Laminopathies).

Lab(s)

Center for Gene Therapy

  • Center for Gene Therapy

                    Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nat Commun. 2021 Dec 8; 12: 7128.



                Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight. 2018 Nov 15; 3: 



                Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev. 2018 Mar 16; 8: 121-130.

View More Publications

  • Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nat Commun. 2021 Dec 8; 12: 7128.
  • Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight. 2018 Nov 15; 3:
  • Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev. 2018 Mar 16; 8: 121-130.

Biography

Nizar Y. Saad, PhD, is a research assistant professor at The Ohio State University College of Medicine, and a principal investigator at the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Saad is an experienced RNA biologist and gene therapy specialist. Dr. Saad also serves on the New Investigator Committee, the Musculo-Skeletal Gene & Cell Therapy Committee and the Oligonucleotide and RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy (ASGCT). Dr. Saad earned his doctorate degree in life sciences (biochemistry and molecular biology) from the University of Strasbourg. Dr. Saad then completed two consecutive postdoctoral training, in the lab of Tina Henkin, PhD, at The Ohio State University, where he investigated bacterial T-box riboswitch-based regulation of gene expression, and in the lab of Scott Harper, PhD, at Nationwide Children’s Hospital, where he developed gene and drug-based therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) by inducing the expression of a natural DUX4-targerting miRNA.

Biography

Nizar Y. Saad, PhD, is a research assistant professor at The Ohio State University College of Medicine, and a principal investigator at the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Saad is an experienced RNA biologist and gene therapy specialist. Dr. Saad also serves on the New Investigator Committee, the Musculo-Skeletal Gene & Cell Therapy Committee and the Oligonucleotide and RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy (ASGCT). Dr. Saad earned his doctorate degree in life sciences (biochemistry and molecular biology) from the University of Strasbourg. Dr. Saad then completed two consecutive postdoctoral training, in the lab of Tina Henkin, PhD, at The Ohio State University, where he investigated bacterial T-box riboswitch-based regulation of gene expression, and in the lab of Scott Harper, PhD, at Nationwide Children’s Hospital, where he developed gene and drug-based therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) by inducing the expression of a natural DUX4-targerting miRNA.

Biography

Nizar Y. Saad, PhD, is a research assistant professor at The Ohio State University College of Medicine, and a principal investigator at the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Saad is an experienced RNA biologist and gene therapy specialist. Dr. Saad also serves on the New Investigator Committee, the Musculo-Skeletal Gene & Cell Therapy Committee and the Oligonucleotide and RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy (ASGCT). Dr. Saad earned his doctorate degree in life sciences (biochemistry and molecular biology) from the University of Strasbourg. Dr. Saad then completed two consecutive postdoctoral training, in the lab of Tina Henkin, PhD, at The Ohio State University, where he investigated bacterial T-box riboswitch-based regulation of gene expression, and in the lab of Scott Harper, PhD, at Nationwide Children’s Hospital, where he developed gene and drug-based therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) by inducing the expression of a natural DUX4-targerting miRNA.

Nizar Y. Saad, PhD, is a research assistant professor at The Ohio State University College of Medicine, and a principal investigator at the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Saad is an experienced RNA biologist and gene therapy specialist. Dr. Saad also serves on the New Investigator Committee, the Musculo-Skeletal Gene & Cell Therapy Committee and the Oligonucleotide and RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy (ASGCT). Dr. Saad earned his doctorate degree in life sciences (biochemistry and molecular biology) from the University of Strasbourg. Dr. Saad then completed two consecutive postdoctoral training, in the lab of Tina Henkin, PhD, at The Ohio State University, where he investigated bacterial T-box riboswitch-based regulation of gene expression, and in the lab of Scott Harper, PhD, at Nationwide Children’s Hospital, where he developed gene and drug-based therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) by inducing the expression of a natural DUX4-targerting miRNA.

Nizar Y. Saad, PhD, is a research assistant professor at The Ohio State University College of Medicine, and a principal investigator at the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Saad is an experienced RNA biologist and gene therapy specialist. Dr. Saad also serves on the New Investigator Committee, the Musculo-Skeletal Gene & Cell Therapy Committee and the Oligonucleotide and RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy (ASGCT).

Dr. Saad earned his doctorate degree in life sciences (biochemistry and molecular biology) from the University of Strasbourg. Dr. Saad then completed two consecutive postdoctoral training, in the lab of Tina Henkin, PhD, at The Ohio State University, where he investigated bacterial T-box riboswitch-based regulation of gene expression, and in the lab of Scott Harper, PhD, at Nationwide Children’s Hospital, where he developed gene and drug-based therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) by inducing the expression of a natural DUX4-targerting miRNA.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

  • Center for Gene Therapy
  • Principal Investigator
  • Primary Department
  • Center for Gene Therapy

Awards, Honors & Organizations

Elsevier WMS Membership Award, World Muscle Society, 2018 Certificate of Recognition from the President of The Ohio State University, The Ohio State University, 2014 FEBS Summer Fellowship, University of Strasbourg, 2009 Member, International Society for Extracellular Vesicles, 2021 - Present Member, American Society for Gene and Cell Therapy, USA, 2019 - Present Member, World Muscle Society, 2018 - Present Member, National Postdoctoral Association, USA, 2013 - 2019

Awards, Honors & Organizations

Elsevier WMS Membership Award, World Muscle Society, 2018 Certificate of Recognition from the President of The Ohio State University, The Ohio State University, 2014 FEBS Summer Fellowship, University of Strasbourg, 2009 Member, International Society for Extracellular Vesicles, 2021 - Present Member, American Society for Gene and Cell Therapy, USA, 2019 - Present Member, World Muscle Society, 2018 - Present Member, National Postdoctoral Association, USA, 2013 - 2019

Awards, Honors & Organizations

Elsevier WMS Membership Award, World Muscle Society, 2018 Certificate of Recognition from the President of The Ohio State University, The Ohio State University, 2014 FEBS Summer Fellowship, University of Strasbourg, 2009 Member, International Society for Extracellular Vesicles, 2021 - Present Member, American Society for Gene and Cell Therapy, USA, 2019 - Present Member, World Muscle Society, 2018 - Present Member, National Postdoctoral Association, USA, 2013 - 2019

Elsevier WMS Membership Award, World Muscle Society, 2018 Certificate of Recognition from the President of The Ohio State University, The Ohio State University, 2014 FEBS Summer Fellowship, University of Strasbourg, 2009 Member, International Society for Extracellular Vesicles, 2021 - Present Member, American Society for Gene and Cell Therapy, USA, 2019 - Present Member, World Muscle Society, 2018 - Present Member, National Postdoctoral Association, USA, 2013 - 2019

  • Elsevier WMS Membership Award, World Muscle Society, 2018
  • Certificate of Recognition from the President of The Ohio State University, The Ohio State University, 2014
  • FEBS Summer Fellowship, University of Strasbourg, 2009
  • Member, International Society for Extracellular Vesicles, 2021 - Present
  • Member, American Society for Gene and Cell Therapy, USA, 2019 - Present
  • Member, World Muscle Society, 2018 - Present
  • Member, National Postdoctoral Association, USA, 2013 - 2019

Education

Graduate School

University of Strasbourg

Date Completed: 08/10/2011

Education

Graduate School

University of Strasbourg

Date Completed: 08/10/2011

Education

Graduate School

University of Strasbourg

Date Completed: 08/10/2011

Graduate School

University of Strasbourg

Date Completed: 08/10/2011

Graduate School

University of Strasbourg

Date Completed: 08/10/2011

Professional Experience

2019 - 2021 Nationwide Children’s Hospital, Research Scientist2015 - 2019 Nationwide Children’s Hospital, Postdoctoral Fellow2013 - 2015 The Ohio State University, Postdoctoral Fellow

Professional Experience

2019 - 2021 Nationwide Children’s Hospital, Research Scientist2015 - 2019 Nationwide Children’s Hospital, Postdoctoral Fellow2013 - 2015 The Ohio State University, Postdoctoral Fellow

Professional Experience

2019 - 2021 Nationwide Children’s Hospital, Research Scientist2015 - 2019 Nationwide Children’s Hospital, Postdoctoral Fellow2013 - 2015 The Ohio State University, Postdoctoral Fellow

2019 - 2021 Nationwide Children’s Hospital, Research Scientist2015 - 2019 Nationwide Children’s Hospital, Postdoctoral Fellow2013 - 2015 The Ohio State University, Postdoctoral Fellow

2019 - 2021 Nationwide Children’s Hospital, Research Scientist

Contact Information

Center for Gene Therapy

Call us at: (614) 355-2787

Email Nizar Y Saad 2

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Gene Therapy

Call us at: (614) 355-2787

Email Nizar Y Saad 2

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Gene Therapy

Call us at: (614) 355-2787

Email Nizar Y Saad 2

                    700 Children's DriveColumbus, OH 43205 (map)

Center for Gene Therapy

Call us at: (614) 355-2787

Email Nizar Y Saad 2

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-2787

Email Nizar Y Saad 2

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-2787

Email Nizar Y Saad 2

                    700 Children's DriveColumbus, OH 43205 (map)
  • Call us at:
  • (614) 355-2787
  • Email Nizar Y Saad 2
  • 700 Children’s DriveColumbus, OH 43205 (map)

Connect with Nizar Y. Saad

Connect on LinkedIn

Connect on ResearchGate